The effect of combination IFN-alpha-2a with usual antituberculosis chemotherapy in non-responding tuberculosis and diabetes mellitus: a case report and review of the literature

References

• Hendy M, Stableforth D. The effect of established diabetes mellitus on the presentation of infiltrative pulmonary tuberculosis in the immigrant Asian community of an inner city area of the United Kingdom. Br J Dis Chest. 1983;77(1):87–90.
   PubMedGoogle Scholar
• Bailey SL, Grant P. ‘The tubercular diabetic’: the impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control. Clin Med. 2011;11(4):344–7.
   Web of Science ®Google Scholar
• Gupta S, Shenoy VP, Bairy I, Srinivasa H, Mukhopadhyay C. Diabetes mellitus and HIV as co-morbidities in tuberculosis patients of rural south India. J Infect Public Health. 2011;4(3):140–4.
   PubMedGoogle Scholar
• Chang JT, Dou HY, Yen CL, Wu YH, Huang RM, Lin HJ, et al.. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc. 2011;110(6):372–81.
   PubMed Web of Science ®Google Scholar
• Walsh MC, Camerlin AJ, Miles R, Pino P, Martinez P, Mora-Guzman F, et al.. The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. Int J Tuberc Lung Dis. 2011;15(2):179–84, i–iii.
   PubMed Web of Science ®Google Scholar
• Silva DR, Menegotto DM, Schulz LF, Gazzana MB, Pde DalcinT. Clinical characteristics and evolution of non-HIV-infected immunocompromised patients with an in-hospital diagnosis of tuberculosis. J Bras Pneumol. 2010;36(4):475–84.
   PubMed Web of Science ®Google Scholar
• Dawson R, Condos R, Tse D, Huie ML, Ress S, Tseng CH, et al.. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One. 2009;4(9):e6984.
   PubMedGoogle Scholar
• Flesch IE, Kaufmann SH. Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages. Infect Immun. 1988;56(6):1464–9.
   PubMed Web of Science ®Google Scholar
• Condos R, Raju B, Canova A, Zhao BY, Weiden M, Rom WN, et al.. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect Immun. 2003;71(4):2058–64.
   PubMed Web of Science ®Google Scholar
• Kahn CR. Autoimmunity and the aetiology of insulin-dependent diabetes mellitus. Nature. 1982;299(5878):15–6.
   PubMed Web of Science ®Google Scholar
• Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221–47.
   Google Scholar
• Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152.
   PubMedGoogle Scholar
• Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737–46.
   PubMed Web of Science ®Google Scholar
• Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, et al.. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis. 2007;45(4):428–35.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80(4):634–9.
   PubMed Web of Science ®Google Scholar
• Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lonnroth K, et al.. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.
   PubMed Web of Science ®Google Scholar
• Giosue S, Casarini M, Ameglio F, Zangrilli P, Palla M, Altieri AM, et al.. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw. 2000;11(1):99–104.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med. 1993;178(5):1655–63.
   PubMed Web of Science ®Google Scholar
• Parronchi P, de Carli M, Manetti R, Simonelli C, Sampognaro S, Piccinni MP, et al.. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol. 1992;149(9):2977–83.
   PubMed Web of Science ®Google Scholar
• Giosue S, Casarini M, Alemanno L, Galluccio G, Mattia P, Pedicelli G, et al.. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 1998;158(4):1156–62.
   PubMed Web of Science ®Google Scholar
• Palmero D, Eiguchi K, Rendo P, Zorrilla CastroL, Abbate E, Montaner GonzalezLJ. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int J Tuberc Lung Dis. 1999;3(3):214–8.
   PubMed Web of Science ®Google Scholar
• Romagnani S. Induction of TH1 and TH2 responses: a key role for the ‘natural’ immune response? Immunol Today. 1992;13(10):379–81.
   PubMedGoogle Scholar
• Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, et al.. Natural killer cell stimulatory factor (interleukin 12 [IL–12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993;177(4):1199–204.
   PubMed Web of Science ®Google Scholar
• Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci. 2011;116(4):227–37.
   PubMed Web of Science ®Google Scholar
• Li XL, Ezelle HJ, Kang TJ, Zhang L, Shirey KA, Harro J, et al.. An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity. Proc Natl Acad Sci USA. 2008;105(52):20816–21.
   PubMed Web of Science ®Google Scholar
• Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005;5(9):675–87.
   PubMed Web of Science ®Google Scholar
• Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab. 1992;18(3):187–201.
   PubMed Web of Science ®Google Scholar
• Yamashiro S, Kawakami K, Uezu K, Kinjo T, Miyagi K, Nakamura K, et al.. Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis. Clin Exp Immunol. 2005;139(1):57–64.
   PubMed Web of Science ®Google Scholar
• Martens GW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis susceptibility of diabetic mice. Am J Respir Cell Mol Biol. 2007;37(5):518–24.
   PubMed Web of Science ®Google Scholar
• Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, et al.. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother. 2010;54(3):1068–74.
   PubMed Web of Science ®Google Scholar
• Lande R, Giacomini E, Grassi T, Remoli ME, Iona E, Miettinen M, et al.. IFN-alpha beta released by Mycobacterium tuberculosis-infected human dendritic cells induces the expression of CXCL10: selective recruitment of NK and activated T cells. J Immunol. 2003;170(3):1174–82.
   PubMed Web of Science ®Google Scholar
• Prabhakar S, Qiao Y, Canova A, Tse DB, Pine R. IFN-alpha beta secreted during infection is necessary but not sufficient for negative feedback regulation of IFN-alpha beta signaling by Mycobacterium tuberculosis. J Immunol. 2005;174(2):1003–12.
   PubMed Web of Science ®Google Scholar
• Kuchtey J, Fulton SA, Reba SM, Harding CV, Boom WH. Interferon-alphabeta mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guerin infection. Immunology. 2006;118(1):39–49.
   PubMed Web of Science ®Google Scholar
• Bouchonnet F, Boechat N, Bonay M, Hance AJ. Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect Immun. 2002;70(6):3020–5.
   PubMed Web of Science ®Google Scholar
• Perez-Elias MJ, Miguel Garcia-SanL, Garcia GonzalezJ, Ramirez MontesML, Muriel A, Machin-Lazaro JM, et al.. Tuberculosis complicating hepatitis C treatment in HIV-infected patients. Clin Infect Dis. 2009;48(8):e82–5.
   PubMed Web of Science ®Google Scholar
• Claassen MA, de Knegt RJ, Janssen HL, Boonstra A. Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans. J Virol. 2011;85(11):5323–30.
   PubMed Web of Science ®Google Scholar
• Atsukawa M, Nakatsuka K, Kobayashi T, Shimizu M, Tamura H, Harimoto H, et al.. Ribavirin down-modulates inducible costimulator on CD4+ T-cells and their interleukin-10 secretion to assist clearance of hepatitis C virus. J Gastroenterol Hepatol. 2012;27(4):823–31.
   PubMed Web of Science ®Google Scholar
• Telesca C, Angelico M, Piccolo P, Nosotti L, Morrone A, Longhi C, et al.. Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J Infect. 2007;54(4):e223–6.
   PubMedGoogle Scholar